drugset / Trial / NCT04824144
Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care
Phase 1/2
Recruiting
50 enrolled
Bruyère Health Research Institute.
Bruyère Continuing Care · collabFoothills Medical Centre · collabThe Ottawa Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this multi-centre phase I/II open-label, single-arm study is to determine the feasibility, optimal dose, and preliminary efficacy of dexmedetomidine to manage agitated delirium among patients near the end of life followed by a palliative care provider in a non-monitored setting. Fifty patients will receive dexmedetomidine (0.4 mcg/kg/hour, titrated up to 1.0 mcg/kg/hour) subcutaneously. Feasibility (recruitment rate, cost), safety (rate of adverse events), dosing, and preliminary efficacy (agitation, delirium severity) will be measured.
Timeline
- Start
- 2024-01-30
- Primary completion
- 2026-01-31
- Completion
- 2026-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexmedetomidine | Other / unclassified | 1 ug/kg | Subcutaneous |